Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy, reflecting the organisation’s commitment to faster, smarter, patient-centred clinical trials,

Lisa brings extensive experience from her time as Senior Medical Assessor at the MHRA, where she led early-phase regulatory reviews, public health emergency responses during the Pandemic (including approvals of COVID-19 platform trials) and represented the MHRA during the development of the Combined Ways of Working with the HRA. Lisa also contributed to the development of ILAP based on lessons learnt from COVID pre-assessment work.

She most recently held the role of Senior Director Medical at SSI Strategy, advising on global regulatory strategy, clinical programme design, and submissions for advanced therapies in rare disease settings.

In her new role, Lisa will oversee all regulatory and medical writing activities, drive capability development, and represent Richmond in regulatory engagements. She will collaborate closely with Clinical Project Delivery, Quality, and Business Development to embed regulatory best practice into all stages of study planning and execution.

“I’m proud to join Richmond at a time of regulatory change and innovation,” said Lisa. “I look forward to contributing to a team that prioritises compliance, collaboration, and patient voice.”